NO870053L - Fremgangsmaate for fremstilling av terapeutisk aktive nitrogenholdige, kondenserte, aromatiske forbindelser. - Google Patents
Fremgangsmaate for fremstilling av terapeutisk aktive nitrogenholdige, kondenserte, aromatiske forbindelser.Info
- Publication number
- NO870053L NO870053L NO870053A NO870053A NO870053L NO 870053 L NO870053 L NO 870053L NO 870053 A NO870053 A NO 870053A NO 870053 A NO870053 A NO 870053A NO 870053 L NO870053 L NO 870053L
- Authority
- NO
- Norway
- Prior art keywords
- compound
- formula
- salt
- carbonylmethyl
- piperazinyl
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 52
- 238000002360 preparation method Methods 0.000 title claims description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 title 2
- 150000001491 aromatic compounds Chemical class 0.000 title 1
- 229910052757 nitrogen Inorganic materials 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 102
- 150000003839 salts Chemical class 0.000 claims description 68
- -1 nitroso, amidino Chemical group 0.000 claims description 46
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 33
- 125000000217 alkyl group Chemical group 0.000 claims description 22
- 229910052739 hydrogen Inorganic materials 0.000 claims description 20
- 239000001257 hydrogen Substances 0.000 claims description 20
- 150000002431 hydrogen Chemical class 0.000 claims description 16
- 229910052736 halogen Inorganic materials 0.000 claims description 10
- 150000002367 halogens Chemical class 0.000 claims description 10
- 125000003118 aryl group Chemical group 0.000 claims description 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 8
- 125000002252 acyl group Chemical group 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 6
- DRVCULVBWNEGTA-UHFFFAOYSA-N 3-[2-(4-aminopiperazin-1-yl)-2-oxoethyl]-5-chloro-1,3-benzothiazol-2-one Chemical compound C1CN(N)CCN1C(=O)CN1C(=O)SC2=CC=C(Cl)C=C21 DRVCULVBWNEGTA-UHFFFAOYSA-N 0.000 claims description 5
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 5
- 125000002947 alkylene group Chemical group 0.000 claims description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 5
- 125000001424 substituent group Chemical group 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 125000001118 alkylidene group Chemical group 0.000 claims description 4
- 125000005843 halogen group Chemical group 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 3
- 125000004414 alkyl thio group Chemical group 0.000 claims description 3
- 238000005804 alkylation reaction Methods 0.000 claims description 3
- 125000003277 amino group Chemical group 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 239000000460 chlorine Substances 0.000 claims description 3
- 229910052801 chlorine Inorganic materials 0.000 claims description 3
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims description 3
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- 239000011737 fluorine Substances 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 2
- 125000000783 acetimidoyl group Chemical group C(C)(=N)* 0.000 claims description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 2
- 125000003435 aroyl group Chemical group 0.000 claims description 2
- 125000005116 aryl carbamoyl group Chemical group 0.000 claims description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 2
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- 125000001589 carboacyl group Chemical group 0.000 claims description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 2
- 230000007062 hydrolysis Effects 0.000 claims description 2
- 238000006460 hydrolysis reaction Methods 0.000 claims description 2
- 238000007034 nitrosation reaction Methods 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 3
- 239000005977 Ethylene Substances 0.000 claims 3
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 3
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- QFHMNFAUXJAINK-UHFFFAOYSA-N [1-(carbamoylamino)-2-methylpropyl]urea Chemical group NC(=O)NC(C(C)C)NC(N)=O QFHMNFAUXJAINK-UHFFFAOYSA-N 0.000 claims 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 claims 1
- 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 83
- 238000002844 melting Methods 0.000 description 74
- 230000008018 melting Effects 0.000 description 74
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 72
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 62
- 238000006243 chemical reaction Methods 0.000 description 58
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 57
- 239000000203 mixture Substances 0.000 description 55
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 51
- 239000002585 base Substances 0.000 description 48
- 239000000243 solution Substances 0.000 description 43
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 42
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 33
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 30
- 238000004458 analytical method Methods 0.000 description 29
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 28
- 238000000921 elemental analysis Methods 0.000 description 28
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
- 239000002904 solvent Substances 0.000 description 20
- 235000011054 acetic acid Nutrition 0.000 description 19
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 16
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 15
- 239000002253 acid Substances 0.000 description 15
- 238000001816 cooling Methods 0.000 description 15
- 239000013078 crystal Substances 0.000 description 15
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 15
- 238000012360 testing method Methods 0.000 description 14
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 14
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 239000000706 filtrate Substances 0.000 description 12
- 239000011541 reaction mixture Substances 0.000 description 12
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 11
- 238000010438 heat treatment Methods 0.000 description 11
- 239000002244 precipitate Substances 0.000 description 10
- BIMFMUNOCZIOAP-UHFFFAOYSA-N 3-[2-(4-aminopiperazin-1-yl)-2-oxoethyl]-5-chloro-1,3-benzothiazol-2-one;hydrochloride Chemical compound Cl.C1CN(N)CCN1C(=O)CN1C(=O)SC2=CC=C(Cl)C=C21 BIMFMUNOCZIOAP-UHFFFAOYSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 150000002391 heterocyclic compounds Chemical class 0.000 description 9
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 9
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 8
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 7
- 239000003638 chemical reducing agent Substances 0.000 description 7
- 239000003960 organic solvent Substances 0.000 description 7
- 238000006722 reduction reaction Methods 0.000 description 7
- 230000007306 turnover Effects 0.000 description 7
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 230000002411 adverse Effects 0.000 description 6
- 239000003054 catalyst Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000004440 column chromatography Methods 0.000 description 6
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 6
- 239000002198 insoluble material Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 6
- 235000019341 magnesium sulphate Nutrition 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 6
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 6
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 5
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 5
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 150000008065 acid anhydrides Chemical class 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 210000002683 foot Anatomy 0.000 description 4
- 235000019253 formic acid Nutrition 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 239000012046 mixed solvent Substances 0.000 description 4
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 235000011181 potassium carbonates Nutrition 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- 238000010998 test method Methods 0.000 description 4
- DLYUQMMRRRQYAE-UHFFFAOYSA-N tetraphosphorus decaoxide Chemical compound O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- AOKCUAFRZCTWLL-UHFFFAOYSA-N 1-(4-aminopiperazin-1-yl)-2-(6-chloro-2-imino-1,3-benzothiazol-3-yl)ethanone Chemical compound C1CN(N)CCN1C(=O)CN1C(=N)SC2=CC(Cl)=CC=C21 AOKCUAFRZCTWLL-UHFFFAOYSA-N 0.000 description 3
- WPOIOEAYDBUGKI-UHFFFAOYSA-N 1-[2-(4-aminopiperazin-1-yl)-2-oxoethyl]-6-chloro-[1,3]thiazolo[5,4-b]pyridin-2-one;hydrochloride Chemical compound Cl.C1CN(N)CCN1C(=O)CN1C(=O)SC2=NC=C(Cl)C=C21 WPOIOEAYDBUGKI-UHFFFAOYSA-N 0.000 description 3
- SYPHZHWTISIDEQ-UHFFFAOYSA-N 1-[2-[4-(benzylideneamino)piperazin-1-yl]-2-oxoethyl]-6-chloroindole-2,3-dione Chemical compound C12=CC(Cl)=CC=C2C(=O)C(=O)N1CC(=O)N(CC1)CCN1N=CC1=CC=CC=C1 SYPHZHWTISIDEQ-UHFFFAOYSA-N 0.000 description 3
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 3
- FVZULXGCDWRZIK-UHFFFAOYSA-N 3-[2-(4-amino-1,4-diazepan-1-yl)-2-oxoethyl]-5-chloro-1,3-benzothiazol-2-one;hydrochloride Chemical compound Cl.C1CN(N)CCCN1C(=O)CN1C(=O)SC2=CC=C(Cl)C=C21 FVZULXGCDWRZIK-UHFFFAOYSA-N 0.000 description 3
- KXFAHCWJYHYOAI-UHFFFAOYSA-N 3-[2-(4-amino-3-methylpiperazin-1-yl)-2-oxoethyl]-5-chloro-1,3-benzothiazol-2-one;hydrochloride Chemical compound Cl.C1CN(N)C(C)CN1C(=O)CN1C(=O)SC2=CC=C(Cl)C=C21 KXFAHCWJYHYOAI-UHFFFAOYSA-N 0.000 description 3
- HSKNLOJEZTXYTP-UHFFFAOYSA-N 3-[2-(4-aminopiperazin-1-yl)-2-oxoethyl]-1,3-benzothiazol-2-one;hydrochloride Chemical compound Cl.C1CN(N)CCN1C(=O)CN1C(=O)SC2=CC=CC=C21 HSKNLOJEZTXYTP-UHFFFAOYSA-N 0.000 description 3
- OOPYTJRZJHGIHZ-UHFFFAOYSA-N 3-[2-(4-aminopiperazin-1-yl)-2-oxoethyl]-4-chloro-1,3-benzothiazol-2-one;hydrochloride Chemical compound Cl.C1CN(N)CCN1C(=O)CN1C(=O)SC2=CC=CC(Cl)=C21 OOPYTJRZJHGIHZ-UHFFFAOYSA-N 0.000 description 3
- AAALPAIGUUQZEU-UHFFFAOYSA-N 3-[2-(4-aminopiperazin-1-yl)-2-oxoethyl]-5-(trifluoromethyl)-1,3-benzothiazol-2-one;hydrochloride Chemical compound Cl.C1CN(N)CCN1C(=O)CN1C(=O)SC2=CC=C(C(F)(F)F)C=C21 AAALPAIGUUQZEU-UHFFFAOYSA-N 0.000 description 3
- ODZPJYIJUIJRQV-UHFFFAOYSA-N 3-[2-(4-aminopiperazin-1-yl)-2-oxoethyl]-5-chloro-1,3-benzoxazol-2-one;hydrochloride Chemical compound Cl.C1CN(N)CCN1C(=O)CN1C(=O)OC2=CC=C(Cl)C=C21 ODZPJYIJUIJRQV-UHFFFAOYSA-N 0.000 description 3
- HLJWDRJVVMDLOY-UHFFFAOYSA-N 3-[2-(4-aminopiperazin-1-yl)-2-oxoethyl]-5-chloro-6-phenyl-1,3-benzothiazol-2-one;hydrochloride Chemical compound Cl.C1CN(N)CCN1C(=O)CN1C(=O)SC2=CC(C=3C=CC=CC=3)=C(Cl)C=C21 HLJWDRJVVMDLOY-UHFFFAOYSA-N 0.000 description 3
- CWPKMUHXFMZSMD-UHFFFAOYSA-N 3-[2-(4-aminopiperazin-1-yl)-2-oxoethyl]-5-methyl-1,3-benzothiazol-2-one;hydrochloride Chemical compound Cl.C12=CC(C)=CC=C2SC(=O)N1CC(=O)N1CCN(N)CC1 CWPKMUHXFMZSMD-UHFFFAOYSA-N 0.000 description 3
- XENZIJZRAZBQOY-UHFFFAOYSA-N 3-[2-(4-aminopiperazin-1-yl)-2-oxoethyl]-6-bromo-5-chloro-1,3-benzothiazol-2-one;hydrochloride Chemical compound Cl.C1CN(N)CCN1C(=O)CN1C(=O)SC2=CC(Br)=C(Cl)C=C21 XENZIJZRAZBQOY-UHFFFAOYSA-N 0.000 description 3
- MVVRQZRGJNMSOV-UHFFFAOYSA-N 3-[2-(4-aminopiperazin-1-yl)-2-oxoethyl]-6-chloro-1,3-benzothiazol-2-one;hydrochloride Chemical compound Cl.C1CN(N)CCN1C(=O)CN1C(=O)SC2=CC(Cl)=CC=C21 MVVRQZRGJNMSOV-UHFFFAOYSA-N 0.000 description 3
- QNZMCUUXLSIRRL-UHFFFAOYSA-N 3-[2-(4-aminopiperazin-1-yl)-2-oxoethyl]-6-nitro-1,3-benzothiazol-2-one;hydrochloride Chemical compound Cl.C1CN(N)CCN1C(=O)CN1C(=O)SC2=CC([N+]([O-])=O)=CC=C21 QNZMCUUXLSIRRL-UHFFFAOYSA-N 0.000 description 3
- RCUIFZRHMYOBSH-UHFFFAOYSA-N 3-[2-(4-aminopiperazin-1-yl)-2-oxoethyl]-7-chloro-1,3-benzothiazol-2-one;hydrochloride Chemical compound Cl.C1CN(N)CCN1C(=O)CN1C(=O)SC2=C(Cl)C=CC=C21 RCUIFZRHMYOBSH-UHFFFAOYSA-N 0.000 description 3
- VDMDBQXVWYVRNF-UHFFFAOYSA-N 3-[2-(4-nitrosopiperazin-1-yl)-2-oxoethyl]-1,3-benzothiazol-2-one Chemical compound C1CN(N=O)CCN1C(=O)CN1C(=O)SC2=CC=CC=C21 VDMDBQXVWYVRNF-UHFFFAOYSA-N 0.000 description 3
- ZWVSOMADXSYSHM-UHFFFAOYSA-N 3-[2-[4-(benzylideneamino)piperazin-1-yl]-2-oxoethyl]-5-chloro-1,3-benzothiazol-2-one Chemical compound C12=CC(Cl)=CC=C2SC(=O)N1CC(=O)N(CC1)CCN1N=CC1=CC=CC=C1 ZWVSOMADXSYSHM-UHFFFAOYSA-N 0.000 description 3
- DNORVVNABISTJJ-UHFFFAOYSA-N 5-chloro-3-[2-(4-nitrosopiperazin-1-yl)-2-oxoethyl]-1,3-benzothiazol-2-one Chemical compound C12=CC(Cl)=CC=C2SC(=O)N1CC(=O)N1CCN(N=O)CC1 DNORVVNABISTJJ-UHFFFAOYSA-N 0.000 description 3
- CXSVYEGSHMLTLL-UHFFFAOYSA-N 5-chloro-3-[2-[4-(2-methylpropylideneamino)piperazin-1-yl]-2-oxoethyl]-1,3-benzothiazol-2-one Chemical compound C1CN(N=CC(C)C)CCN1C(=O)CN1C(=O)SC2=CC=C(Cl)C=C21 CXSVYEGSHMLTLL-UHFFFAOYSA-N 0.000 description 3
- JQNQHJCDBPGYDV-UHFFFAOYSA-N 6-chloro-1-[2-(4-nitrosopiperazin-1-yl)-2-oxoethyl]-[1,3]thiazolo[5,4-b]pyridin-2-one Chemical compound C12=CC(Cl)=CN=C2SC(=O)N1CC(=O)N1CCN(N=O)CC1 JQNQHJCDBPGYDV-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 3
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 3
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 229910017052 cobalt Inorganic materials 0.000 description 3
- 239000010941 cobalt Substances 0.000 description 3
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 3
- 229910052802 copper Inorganic materials 0.000 description 3
- 239000010949 copper Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- OWFXIOWLTKNBAP-UHFFFAOYSA-N isoamyl nitrite Chemical compound CC(C)CCON=O OWFXIOWLTKNBAP-UHFFFAOYSA-N 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Substances OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 3
- FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 3
- 210000004623 platelet-rich plasma Anatomy 0.000 description 3
- 229910052697 platinum Inorganic materials 0.000 description 3
- 235000019260 propionic acid Nutrition 0.000 description 3
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 2
- VNGYECUMQJJJGT-UHFFFAOYSA-N 1-phenyl-n-piperazin-1-ylmethanimine Chemical compound C1CNCCN1N=CC1=CC=CC=C1 VNGYECUMQJJJGT-UHFFFAOYSA-N 0.000 description 2
- XHDYPSPRTWSYRO-UHFFFAOYSA-N 2-(6-chloro-2-oxo-[1,3]thiazolo[5,4-b]pyridin-1-yl)acetic acid Chemical compound ClC1=CN=C2SC(=O)N(CC(=O)O)C2=C1 XHDYPSPRTWSYRO-UHFFFAOYSA-N 0.000 description 2
- MCQYLUHUVOSPMP-UHFFFAOYSA-N 3-(2-oxo-2-piperazin-1-ylethyl)-1,3-benzothiazol-2-one Chemical compound C12=CC=CC=C2SC(=O)N1CC(=O)N1CCNCC1 MCQYLUHUVOSPMP-UHFFFAOYSA-N 0.000 description 2
- HFBWUANBGYVTOH-UHFFFAOYSA-N 3-[2-(4-nitrosopiperazin-1-yl)-2-oxoethyl]-5-(trifluoromethyl)-1,3-benzothiazol-2-one Chemical compound C12=CC(C(F)(F)F)=CC=C2SC(=O)N1CC(=O)N1CCN(N=O)CC1 HFBWUANBGYVTOH-UHFFFAOYSA-N 0.000 description 2
- LDELGGAACPJXET-UHFFFAOYSA-N 3-[2-[4-(benzylideneamino)piperazin-1-yl]-2-oxoethyl]-6-nitro-1,3-benzothiazol-2-one Chemical compound O=C1SC2=CC([N+](=O)[O-])=CC=C2N1CC(=O)N(CC1)CCN1N=CC1=CC=CC=C1 LDELGGAACPJXET-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- ZMSBIZVKHOWRIX-UHFFFAOYSA-N 4-[2-(5-chloro-2-oxo-1,3-benzothiazol-3-yl)acetyl]piperazine-1-carboximidamide Chemical compound C1CN(C(=N)N)CCN1C(=O)CN1C(=O)SC2=CC=C(Cl)C=C21 ZMSBIZVKHOWRIX-UHFFFAOYSA-N 0.000 description 2
- WMDVTQSRURLTLT-UHFFFAOYSA-N 4-chloro-3-[2-(4-nitrosopiperazin-1-yl)-2-oxoethyl]-1,3-benzothiazol-2-one Chemical compound C1=2C(Cl)=CC=CC=2SC(=O)N1CC(=O)N1CCN(N=O)CC1 WMDVTQSRURLTLT-UHFFFAOYSA-N 0.000 description 2
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 2
- RXZZAYCRMQNTBJ-UHFFFAOYSA-N 5-chloro-3-[2-(3-methyl-4-nitrosopiperazin-1-yl)-2-oxoethyl]-1,3-benzothiazol-2-one Chemical compound C1CN(N=O)C(C)CN1C(=O)CN1C(=O)SC2=CC=C(Cl)C=C21 RXZZAYCRMQNTBJ-UHFFFAOYSA-N 0.000 description 2
- WBHQLACKXLJVMP-UHFFFAOYSA-N 5-chloro-3-[2-(4-nitroso-1,4-diazepan-1-yl)-2-oxoethyl]-1,3-benzothiazol-2-one Chemical compound C12=CC(Cl)=CC=C2SC(=O)N1CC(=O)N1CCCN(N=O)CC1 WBHQLACKXLJVMP-UHFFFAOYSA-N 0.000 description 2
- GDPNSLPBKPRZLA-UHFFFAOYSA-N 5-chloro-3-[2-(4-nitrosopiperazin-1-yl)-2-oxoethyl]-1,3-benzoxazol-2-one Chemical compound C12=CC(Cl)=CC=C2OC(=O)N1CC(=O)N1CCN(N=O)CC1 GDPNSLPBKPRZLA-UHFFFAOYSA-N 0.000 description 2
- ZEUQKYYAMZXNNS-UHFFFAOYSA-N 5-chloro-3-[2-(4-nitrosopiperazin-1-yl)-2-oxoethyl]-6-phenyl-1,3-benzothiazol-2-one Chemical compound O=C1SC=2C=C(C=3C=CC=CC=3)C(Cl)=CC=2N1CC(=O)N1CCN(N=O)CC1 ZEUQKYYAMZXNNS-UHFFFAOYSA-N 0.000 description 2
- OWJUXBUUQNREIC-UHFFFAOYSA-N 5-chloro-3-[2-[4-(methylamino)piperazin-1-yl]-2-oxoethyl]-1,3-benzothiazol-2-one;hydrochloride Chemical compound Cl.C1CN(NC)CCN1C(=O)CN1C(=O)SC2=CC=C(Cl)C=C21 OWJUXBUUQNREIC-UHFFFAOYSA-N 0.000 description 2
- YMLYLENUHDAXPI-UHFFFAOYSA-N 5-chloro-3-[2-[4-(methylideneamino)piperazin-1-yl]-2-oxoethyl]-1,3-benzothiazol-2-one Chemical compound C12=CC(Cl)=CC=C2SC(=O)N1CC(=O)N1CCN(N=C)CC1 YMLYLENUHDAXPI-UHFFFAOYSA-N 0.000 description 2
- QCWRTSPGJNIDMU-UHFFFAOYSA-N 5-methyl-3-[2-(4-nitrosopiperazin-1-yl)-2-oxoethyl]-1,3-benzothiazol-2-one Chemical compound C12=CC(C)=CC=C2SC(=O)N1CC(=O)N1CCN(N=O)CC1 QCWRTSPGJNIDMU-UHFFFAOYSA-N 0.000 description 2
- LBYYYJZFFTWPES-UHFFFAOYSA-N 6-bromo-5-chloro-3-[2-(4-nitrosopiperazin-1-yl)-2-oxoethyl]-1,3-benzothiazol-2-one Chemical compound O=C1SC=2C=C(Br)C(Cl)=CC=2N1CC(=O)N1CCN(N=O)CC1 LBYYYJZFFTWPES-UHFFFAOYSA-N 0.000 description 2
- GNLRDIZQZQWVNJ-UHFFFAOYSA-N 6-chloro-1-(2-oxo-2-piperazin-1-ylethyl)-[1,3]thiazolo[5,4-b]pyridin-2-one Chemical compound C12=CC(Cl)=CN=C2SC(=O)N1CC(=O)N1CCNCC1 GNLRDIZQZQWVNJ-UHFFFAOYSA-N 0.000 description 2
- HFLUEPQJJWCETM-UHFFFAOYSA-N 6-chloro-1h-[1,3]thiazolo[5,4-b]pyridin-2-one Chemical compound ClC1=CN=C2SC(O)=NC2=C1 HFLUEPQJJWCETM-UHFFFAOYSA-N 0.000 description 2
- FKURITLNBGFRJO-UHFFFAOYSA-N 6-chloro-3-[2-(4-nitrosopiperazin-1-yl)-2-oxoethyl]-1,3-benzothiazol-2-one Chemical compound O=C1SC2=CC(Cl)=CC=C2N1CC(=O)N1CCN(N=O)CC1 FKURITLNBGFRJO-UHFFFAOYSA-N 0.000 description 2
- ORUAEARTGSBEBY-UHFFFAOYSA-N 7-chloro-3-[2-(4-nitrosopiperazin-1-yl)-2-oxoethyl]-1,3-benzothiazol-2-one Chemical compound O=C1SC=2C(Cl)=CC=CC=2N1CC(=O)N1CCN(N=O)CC1 ORUAEARTGSBEBY-UHFFFAOYSA-N 0.000 description 2
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 206010030124 Oedema peripheral Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 150000001350 alkyl halides Chemical class 0.000 description 2
- 150000008051 alkyl sulfates Chemical class 0.000 description 2
- 150000008052 alkyl sulfonates Chemical class 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000002785 anti-thrombosis Effects 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 150000001540 azides Chemical class 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 2
- XJHCXCQVJFPJIK-UHFFFAOYSA-M caesium fluoride Chemical compound [F-].[Cs+] XJHCXCQVJFPJIK-UHFFFAOYSA-M 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 238000010531 catalytic reduction reaction Methods 0.000 description 2
- QQVDYSUDFZZPSU-UHFFFAOYSA-M chloromethylidene(dimethyl)azanium;chloride Chemical compound [Cl-].C[N+](C)=CCl QQVDYSUDFZZPSU-UHFFFAOYSA-M 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- ZFZRVSVXKUUARQ-UHFFFAOYSA-N ethyl n-[4-[2-(5-chloro-2-oxo-1,3-benzothiazol-3-yl)acetyl]piperazin-1-yl]carbamate Chemical compound C1CN(NC(=O)OCC)CCN1C(=O)CN1C(=O)SC2=CC=C(Cl)C=C21 ZFZRVSVXKUUARQ-UHFFFAOYSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000008098 formaldehyde solution Substances 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 2
- SZFDLJGVIDRSON-UHFFFAOYSA-N methyl 2-(6-chloro-2-oxo-[1,3]thiazolo[5,4-b]pyridin-1-yl)acetate Chemical compound ClC1=CN=C2SC(=O)N(CC(=O)OC)C2=C1 SZFDLJGVIDRSON-UHFFFAOYSA-N 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- BHOYYWLIHALYCG-UHFFFAOYSA-N n'-[4-[2-(5-chloro-2-oxo-1,3-benzothiazol-3-yl)acetyl]piperazin-1-yl]ethanimidamide;hydrochloride Chemical compound Cl.C1CN(/N=C(N)/C)CCN1C(=O)CN1C(=O)SC2=CC=C(Cl)C=C21 BHOYYWLIHALYCG-UHFFFAOYSA-N 0.000 description 2
- ITXSNVMDHOWIIP-UHFFFAOYSA-N n-[4-[2-(5-chloro-2-oxo-1,3-benzothiazol-3-yl)acetyl]piperazin-1-yl]acetamide Chemical compound C1CN(NC(=O)C)CCN1C(=O)CN1C(=O)SC2=CC=C(Cl)C=C21 ITXSNVMDHOWIIP-UHFFFAOYSA-N 0.000 description 2
- LKBDDGOKAAKXPB-UHFFFAOYSA-N n-[4-[2-(5-chloro-2-oxo-1,3-benzothiazol-3-yl)acetyl]piperazin-1-yl]formamide Chemical compound C12=CC(Cl)=CC=C2SC(=O)N1CC(=O)N1CCN(NC=O)CC1 LKBDDGOKAAKXPB-UHFFFAOYSA-N 0.000 description 2
- ZKRNRUQPMBPFMM-UHFFFAOYSA-N n-[4-[2-(5-chloro-2-oxo-1,3-benzothiazol-3-yl)acetyl]piperazin-1-yl]methanesulfonamide Chemical compound C1CN(NS(=O)(=O)C)CCN1C(=O)CN1C(=O)SC2=CC=C(Cl)C=C21 ZKRNRUQPMBPFMM-UHFFFAOYSA-N 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 229940092253 ovalbumin Drugs 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 2
- 125000004742 propyloxycarbonyl group Chemical group 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- 238000013222 sprague-dawley male rat Methods 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- AKYYURPUIANXHR-UHFFFAOYSA-N (4-nitrophenyl)methyl (nz)-n-(1-aminoethylidene)carbamate Chemical compound CC(=N)NC(=O)OCC1=CC=C([N+]([O-])=O)C=C1 AKYYURPUIANXHR-UHFFFAOYSA-N 0.000 description 1
- AETUKWKXMDYFMQ-UHFFFAOYSA-N (4-nitrophenyl)methyl 3-amino-3-[4-[2-(5-chloro-2-oxo-1,3-benzothiazol-3-yl)acetyl]piperazin-1-yl]iminopropanoate Chemical compound C1=CC([N+](=O)[O-])=CC=C1COC(=O)CC(=N)NN1CCN(C(=O)CN2C(SC3=CC=C(Cl)C=C32)=O)CC1 AETUKWKXMDYFMQ-UHFFFAOYSA-N 0.000 description 1
- VGRXAHXMIDCTNV-UHFFFAOYSA-N (6-chlorobenzotriazol-1-yl) 4-chlorobenzenesulfonate Chemical compound C1=CC(Cl)=CC=C1S(=O)(=O)ON1C2=CC(Cl)=CC=C2N=N1 VGRXAHXMIDCTNV-UHFFFAOYSA-N 0.000 description 1
- SGUVLZREKBPKCE-UHFFFAOYSA-N 1,5-diazabicyclo[4.3.0]-non-5-ene Chemical compound C1CCN=C2CCCN21 SGUVLZREKBPKCE-UHFFFAOYSA-N 0.000 description 1
- MXBGSQUWTZHIFD-UHFFFAOYSA-N 1-[2-(4-aminopiperazin-1-yl)-2-oxoethyl]-6-chloro-3-hydroxyiminoindol-2-one;hydrochloride Chemical compound Cl.C1CN(N)CCN1C(=O)CN1C2=CC(Cl)=CC=C2C(=NO)C1=O MXBGSQUWTZHIFD-UHFFFAOYSA-N 0.000 description 1
- BTMWQUOFMDLPFB-UHFFFAOYSA-N 1-[4-(benzylideneamino)piperazin-1-yl]-2-(6-chloro-2-imino-1,3-benzothiazol-3-yl)ethanone Chemical compound N=C1SC2=CC(Cl)=CC=C2N1CC(=O)N(CC1)CCN1N=CC1=CC=CC=C1 BTMWQUOFMDLPFB-UHFFFAOYSA-N 0.000 description 1
- NILDMHBGKFECBL-UHFFFAOYSA-N 1-[4-[2-(5-chloro-2-oxo-1,3-benzothiazol-3-yl)acetyl]piperazin-1-yl]-3-(4-fluorophenyl)urea Chemical compound C1=CC(F)=CC=C1NC(=O)NN1CCN(C(=O)CN2C(SC3=CC=C(Cl)C=C32)=O)CC1 NILDMHBGKFECBL-UHFFFAOYSA-N 0.000 description 1
- DSVGFKBFFICWLZ-UHFFFAOYSA-N 1-fluoro-4-isocyanatobenzene Chemical compound FC1=CC=C(N=C=O)C=C1 DSVGFKBFFICWLZ-UHFFFAOYSA-N 0.000 description 1
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
- SXOCCTHWTPGZHT-UHFFFAOYSA-N 2-(2-oxo-1,3-benzothiazol-3-yl)acetic acid Chemical compound C1=CC=C2SC(=O)N(CC(=O)O)C2=C1 SXOCCTHWTPGZHT-UHFFFAOYSA-N 0.000 description 1
- MYTTVLWLGMIDQY-UHFFFAOYSA-N 2-(5-chloro-2-oxo-1,3-benzothiazol-3-yl)acetic acid Chemical compound ClC1=CC=C2SC(=O)N(CC(=O)O)C2=C1 MYTTVLWLGMIDQY-UHFFFAOYSA-N 0.000 description 1
- CFMZSMGAMPBRBE-UHFFFAOYSA-N 2-hydroxyisoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(O)C(=O)C2=C1 CFMZSMGAMPBRBE-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- SDXAWLJRERMRKF-UHFFFAOYSA-N 3,5-dimethyl-1h-pyrazole Chemical compound CC=1C=C(C)NN=1 SDXAWLJRERMRKF-UHFFFAOYSA-N 0.000 description 1
- IJXCDYMALCJKGE-UHFFFAOYSA-N 3-(2-oxo-2-piperazin-1-ylethyl)-5-(trifluoromethyl)-1,3-benzothiazol-2-one Chemical compound C12=CC(C(F)(F)F)=CC=C2SC(=O)N1CC(=O)N1CCNCC1 IJXCDYMALCJKGE-UHFFFAOYSA-N 0.000 description 1
- JCGQOOJMGCBJDI-UHFFFAOYSA-N 3-amino-5-chloro-1h-pyridine-2-thione Chemical compound NC1=CC(Cl)=CN=C1S JCGQOOJMGCBJDI-UHFFFAOYSA-N 0.000 description 1
- CSDQQAQKBAQLLE-UHFFFAOYSA-N 4-(4-chlorophenyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine Chemical compound C1=CC(Cl)=CC=C1C1C(C=CS2)=C2CCN1 CSDQQAQKBAQLLE-UHFFFAOYSA-N 0.000 description 1
- WTVKGEUXWKAEJF-UHFFFAOYSA-N 4-chloro-3-(2-oxo-2-piperazin-1-ylethyl)-1,3-benzothiazol-2-one Chemical compound C1=2C(Cl)=CC=CC=2SC(=O)N1CC(=O)N1CCNCC1 WTVKGEUXWKAEJF-UHFFFAOYSA-N 0.000 description 1
- CZKLEJHVLCMVQR-UHFFFAOYSA-N 4-fluorobenzoyl chloride Chemical compound FC1=CC=C(C(Cl)=O)C=C1 CZKLEJHVLCMVQR-UHFFFAOYSA-N 0.000 description 1
- RPRUIZPTDDIOHH-UHFFFAOYSA-N 5-chloro-3-(2-oxo-2-piperazin-1-ylethyl)-1,3-benzothiazol-2-one Chemical compound C12=CC(Cl)=CC=C2SC(=O)N1CC(=O)N1CCNCC1 RPRUIZPTDDIOHH-UHFFFAOYSA-N 0.000 description 1
- PPLWVWZTCFFXMI-UHFFFAOYSA-N 5-chloro-3-(2-oxo-2-piperazin-1-ylethyl)-1,3-benzoxazol-2-one Chemical compound C12=CC(Cl)=CC=C2OC(=O)N1CC(=O)N1CCNCC1 PPLWVWZTCFFXMI-UHFFFAOYSA-N 0.000 description 1
- PJIJLHJWNLMULI-UHFFFAOYSA-N 5-chloro-3-(2-oxo-2-piperazin-1-ylethyl)-6-phenyl-1,3-benzothiazol-2-one Chemical compound O=C1SC=2C=C(C=3C=CC=CC=3)C(Cl)=CC=2N1CC(=O)N1CCNCC1 PJIJLHJWNLMULI-UHFFFAOYSA-N 0.000 description 1
- DFRJZCIRUKNORO-UHFFFAOYSA-N 5-chloro-3-[2-(1,4-diazepan-1-yl)-2-oxoethyl]-1,3-benzothiazol-2-one Chemical compound C12=CC(Cl)=CC=C2SC(=O)N1CC(=O)N1CCCNCC1 DFRJZCIRUKNORO-UHFFFAOYSA-N 0.000 description 1
- XWBROIXYCCKXMT-UHFFFAOYSA-N 5-chloro-3-[2-(3-methylpiperazin-1-yl)-2-oxoethyl]-1,3-benzothiazol-2-one Chemical compound C1CNC(C)CN1C(=O)CN1C(=O)SC2=CC=C(Cl)C=C21 XWBROIXYCCKXMT-UHFFFAOYSA-N 0.000 description 1
- MLMIOVMKWAOSOC-UHFFFAOYSA-N 5-chloro-3-[2-[4-(dimethylamino)piperazin-1-yl]-2-oxoethyl]-1,3-benzothiazol-2-one;hydrochloride Chemical compound Cl.C1CN(N(C)C)CCN1C(=O)CN1C(=O)SC2=CC=C(Cl)C=C21 MLMIOVMKWAOSOC-UHFFFAOYSA-N 0.000 description 1
- VUFAPOLHIQCRIB-UHFFFAOYSA-N 5-methyl-3-(2-oxo-2-piperazin-1-ylethyl)-1,3-benzothiazol-2-one Chemical compound C12=CC(C)=CC=C2SC(=O)N1CC(=O)N1CCNCC1 VUFAPOLHIQCRIB-UHFFFAOYSA-N 0.000 description 1
- JMCLAOUDFDXUCP-UHFFFAOYSA-N 6-bromo-5-chloro-3-(2-oxo-2-piperazin-1-ylethyl)-1,3-benzothiazol-2-one Chemical compound O=C1SC=2C=C(Br)C(Cl)=CC=2N1CC(=O)N1CCNCC1 JMCLAOUDFDXUCP-UHFFFAOYSA-N 0.000 description 1
- QTWWTEQKBVYJBN-UHFFFAOYSA-N 6-chloro-3-(2-oxo-2-piperazin-1-ylethyl)-1,3-benzothiazol-2-one Chemical compound O=C1SC2=CC(Cl)=CC=C2N1CC(=O)N1CCNCC1 QTWWTEQKBVYJBN-UHFFFAOYSA-N 0.000 description 1
- DPGFSWLZVNOFJE-UHFFFAOYSA-N 7-chloro-3-(2-oxo-2-piperazin-1-ylethyl)-1,3-benzothiazol-2-one Chemical compound O=C1SC=2C(Cl)=CC=CC=2N1CC(=O)N1CCNCC1 DPGFSWLZVNOFJE-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- 229910021555 Chromium Chloride Inorganic materials 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical class NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- 239000012448 Lithium borohydride Substances 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- CVTIZMOISGMZRJ-UHFFFAOYSA-N N-Mononitrosopiperazine Chemical compound O=NN1CCNCC1 CVTIZMOISGMZRJ-UHFFFAOYSA-N 0.000 description 1
- PHSPJQZRQAJPPF-UHFFFAOYSA-N N-alpha-Methylhistamine Chemical compound CNCCC1=CN=CN1 PHSPJQZRQAJPPF-UHFFFAOYSA-N 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- UKNGDQSYPNBJAO-UHFFFAOYSA-N Tiaramide hydrochloride Chemical compound Cl.C1CN(CCO)CCN1C(=O)CN1C(=O)SC2=CC=C(Cl)C=C21 UKNGDQSYPNBJAO-UHFFFAOYSA-N 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 150000007933 aliphatic carboxylic acids Chemical class 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 229910001515 alkali metal fluoride Inorganic materials 0.000 description 1
- 229910000102 alkali metal hydride Inorganic materials 0.000 description 1
- 150000008046 alkali metal hydrides Chemical class 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical compound [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 125000000637 arginyl group Chemical class N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- SIOVKLKJSOKLIF-UHFFFAOYSA-N bis(trimethylsilyl)acetamide Chemical compound C[Si](C)(C)OC(C)=N[Si](C)(C)C SIOVKLKJSOKLIF-UHFFFAOYSA-N 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- FLLNLJJKHKZKMB-UHFFFAOYSA-N boron;tetramethylazanium Chemical compound [B].C[N+](C)(C)C FLLNLJJKHKZKMB-UHFFFAOYSA-N 0.000 description 1
- 125000005997 bromomethyl group Chemical group 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N butyric aldehyde Natural products CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 150000001728 carbonyl compounds Chemical class 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- QSWDMMVNRMROPK-UHFFFAOYSA-K chromium(3+) trichloride Chemical compound [Cl-].[Cl-].[Cl-].[Cr+3] QSWDMMVNRMROPK-UHFFFAOYSA-K 0.000 description 1
- WYYQVWLEPYFFLP-UHFFFAOYSA-K chromium(3+);triacetate Chemical compound [Cr+3].CC([O-])=O.CC([O-])=O.CC([O-])=O WYYQVWLEPYFFLP-UHFFFAOYSA-K 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 125000002592 cumenyl group Chemical group C1(=C(C=CC=C1)*)C(C)C 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 125000000664 diazo group Chemical group [N-]=[N+]=[*] 0.000 description 1
- WLXALCKAKGDNAT-UHFFFAOYSA-N diazoethane Chemical compound CC=[N+]=[N-] WLXALCKAKGDNAT-UHFFFAOYSA-N 0.000 description 1
- 125000004772 dichloromethyl group Chemical group [H]C(Cl)(Cl)* 0.000 description 1
- DENRZWYUOJLTMF-UHFFFAOYSA-N diethyl sulfate Chemical compound CCOS(=O)(=O)OCC DENRZWYUOJLTMF-UHFFFAOYSA-N 0.000 description 1
- 229940008406 diethyl sulfate Drugs 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005935 hexyloxycarbonyl group Chemical group 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910003480 inorganic solid Inorganic materials 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- ANAFTYVSHCSQPP-UHFFFAOYSA-N lithium;trimethoxyalumane Chemical compound [Li].CO[Al](OC)OC ANAFTYVSHCSQPP-UHFFFAOYSA-N 0.000 description 1
- HTBVGZAVHBZXMS-UHFFFAOYSA-N lithium;tris[(2-methylpropan-2-yl)oxy]alumane Chemical compound [Li].[Al+3].CC(C)(C)[O-].CC(C)(C)[O-].CC(C)(C)[O-] HTBVGZAVHBZXMS-UHFFFAOYSA-N 0.000 description 1
- RSHAOIXHUHAZPM-UHFFFAOYSA-N magnesium hydride Chemical compound [MgH2] RSHAOIXHUHAZPM-UHFFFAOYSA-N 0.000 description 1
- 229910012375 magnesium hydride Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 150000002736 metal compounds Chemical class 0.000 description 1
- 229910052987 metal hydride Inorganic materials 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- QABLOFMHHSOFRJ-UHFFFAOYSA-N methyl 2-chloroacetate Chemical compound COC(=O)CCl QABLOFMHHSOFRJ-UHFFFAOYSA-N 0.000 description 1
- VUQUOGPMUUJORT-UHFFFAOYSA-N methyl 4-methylbenzenesulfonate Chemical compound COS(=O)(=O)C1=CC=C(C)C=C1 VUQUOGPMUUJORT-UHFFFAOYSA-N 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- VJBKXYXYWUFPFQ-UHFFFAOYSA-N n-[4-[2-(5-chloro-2-oxo-1,3-benzothiazol-3-yl)acetyl]piperazin-1-yl]-4-fluorobenzamide Chemical compound C1=CC(F)=CC=C1C(=O)NN1CCN(C(=O)CN2C(SC3=CC=C(Cl)C=C32)=O)CC1 VJBKXYXYWUFPFQ-UHFFFAOYSA-N 0.000 description 1
- LWFWUJCJKPUZLV-UHFFFAOYSA-N n-trimethylsilylacetamide Chemical compound CC(=O)N[Si](C)(C)C LWFWUJCJKPUZLV-UHFFFAOYSA-N 0.000 description 1
- 125000001038 naphthoyl group Chemical group C1(=CC=CC2=CC=CC=C12)C(=O)* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229910000480 nickel oxide Inorganic materials 0.000 description 1
- 230000009935 nitrosation Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- ZWLPBLYKEWSWPD-UHFFFAOYSA-N o-toluenecarboxylic acid Natural products CC1=CC=CC=C1C(O)=O ZWLPBLYKEWSWPD-UHFFFAOYSA-N 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- GNRSAWUEBMWBQH-UHFFFAOYSA-N oxonickel Chemical compound [Ni]=O GNRSAWUEBMWBQH-UHFFFAOYSA-N 0.000 description 1
- HBEQXAKJSGXAIQ-UHFFFAOYSA-N oxopalladium Chemical compound [Pd]=O HBEQXAKJSGXAIQ-UHFFFAOYSA-N 0.000 description 1
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 1
- LPNBBFKOUUSUDB-UHFFFAOYSA-N p-toluic acid Chemical compound CC1=CC=C(C(O)=O)C=C1 LPNBBFKOUUSUDB-UHFFFAOYSA-N 0.000 description 1
- 229940124641 pain reliever Drugs 0.000 description 1
- 229910003445 palladium oxide Inorganic materials 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000001148 pentyloxycarbonyl group Chemical group 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- DGTNSSLYPYDJGL-UHFFFAOYSA-N phenyl isocyanate Chemical compound O=C=NC1=CC=CC=C1 DGTNSSLYPYDJGL-UHFFFAOYSA-N 0.000 description 1
- CMPQUABWPXYYSH-UHFFFAOYSA-N phenyl phosphate Chemical compound OP(O)(=O)OC1=CC=CC=C1 CMPQUABWPXYYSH-UHFFFAOYSA-N 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
- IYPZRUYMFDWKSS-UHFFFAOYSA-N piperazin-1-amine Chemical compound NN1CCNCC1 IYPZRUYMFDWKSS-UHFFFAOYSA-N 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 229910003446 platinum oxide Inorganic materials 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 239000011698 potassium fluoride Substances 0.000 description 1
- 235000003270 potassium fluoride Nutrition 0.000 description 1
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 1
- 229910000105 potassium hydride Inorganic materials 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229910052718 tin Inorganic materials 0.000 description 1
- 239000011135 tin Substances 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 1
- RXJKFRMDXUJTEX-UHFFFAOYSA-N triethylphosphine Chemical compound CCP(CC)CC RXJKFRMDXUJTEX-UHFFFAOYSA-N 0.000 description 1
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 125000005023 xylyl group Chemical group 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/38—Oxygen atoms in positions 2 and 3, e.g. isatin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Indole Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB868601160A GB8601160D0 (en) | 1986-01-17 | 1986-01-17 | Heterocyclic compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
NO870053D0 NO870053D0 (no) | 1987-01-06 |
NO870053L true NO870053L (no) | 1987-07-20 |
Family
ID=10591560
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO870053A NO870053L (no) | 1986-01-17 | 1987-01-06 | Fremgangsmaate for fremstilling av terapeutisk aktive nitrogenholdige, kondenserte, aromatiske forbindelser. |
Country Status (14)
Country | Link |
---|---|
US (1) | US4797399A (fr) |
EP (1) | EP0232740A1 (fr) |
JP (1) | JPS62181253A (fr) |
KR (1) | KR870007163A (fr) |
CN (1) | CN87100707A (fr) |
AU (1) | AU6762687A (fr) |
DK (1) | DK8687A (fr) |
FI (1) | FI865369A (fr) |
GB (1) | GB8601160D0 (fr) |
IL (1) | IL81172A0 (fr) |
NO (1) | NO870053L (fr) |
OA (1) | OA08462A (fr) |
PT (1) | PT84103A (fr) |
ZA (1) | ZA869748B (fr) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2601366B1 (fr) * | 1986-07-10 | 1988-11-25 | Andre Buzas | Derives de la benzhydryloxyethyl-piperazine, procedes d'obtention et de compositions pharmaceutiques les contenant. |
GB8714596D0 (en) * | 1987-06-22 | 1987-07-29 | Fujisawa Pharmaceutical Co | Thiazolopyridine compounds |
FI95572C (fi) | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi |
FR2663929A1 (fr) * | 1990-06-29 | 1992-01-03 | Adir | Nouveaux derives d'oxazolo pyridines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
FR2669336B1 (fr) * | 1990-11-20 | 1993-01-22 | Adir | Nouveaux derives d'oxazolo pyridines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent. |
IT1251144B (it) * | 1991-07-30 | 1995-05-04 | Boehringer Ingelheim Italia | Derivati del benzimidazolone |
IL115420A0 (en) | 1994-09-26 | 1995-12-31 | Zeneca Ltd | Aminoheterocyclic derivatives |
EP0880501A1 (fr) | 1996-02-02 | 1998-12-02 | Zeneca Limited | Composes heterocycliques utiles en tant qu'agents pharmaceutiques |
GB9602294D0 (en) * | 1996-02-05 | 1996-04-03 | Zeneca Ltd | Heterocyclic compounds |
DE19618999A1 (de) * | 1996-05-10 | 1997-11-13 | Klinge Co Chem Pharm Fab | Neue Benzothiazolinone |
DE19618970A1 (de) * | 1996-05-10 | 1997-11-13 | Klinge Co Chem Pharm Fab | Neue Thiazolopyridine |
PL331599A1 (en) * | 1996-08-14 | 1999-08-02 | Zeneca Ltd | Substituted derivatives of pyrimidine and their pharmaceutical application |
UA56197C2 (uk) | 1996-11-08 | 2003-05-15 | Зенека Лімітед | Гетероциклічні похідні |
JP2001511798A (ja) | 1997-02-13 | 2001-08-14 | ゼネカ・リミテッド | オキシド−スクアレンシクラーゼ抑制剤として有用な複素環化合物 |
AU5999798A (en) | 1997-02-13 | 1998-09-08 | Zeneca Limited | Heterocyclic compounds useful as oxido-squalene cyclase inhibitors |
HUP0100179A3 (en) | 1997-07-03 | 2002-12-28 | Bristol Myers Squibb Pharma Co | Imidazopyrimidine and imidazopyridine derivatives and pharmaceutical compositions thereof |
GB9715895D0 (en) | 1997-07-29 | 1997-10-01 | Zeneca Ltd | Heterocyclic compounds |
CN1109025C (zh) * | 1997-10-09 | 2003-05-21 | 藤泽药品工业株式会社 | 氨基哌嗪衍生物的新制造法 |
US6124463A (en) * | 1998-07-02 | 2000-09-26 | Dupont Pharmaceuticals | Benzimidazoles as corticotropin release factor antagonists |
US6365589B1 (en) | 1998-07-02 | 2002-04-02 | Bristol-Myers Squibb Pharma Company | Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists |
GB9902989D0 (en) | 1999-02-11 | 1999-03-31 | Zeneca Ltd | Heterocyclic derivatives |
AU7887501A (en) * | 2000-07-06 | 2002-01-21 | Us Gov Health & Human Serv | Tetrahydrobenzothiazole analogues as neuroprotective agents |
US7183410B2 (en) * | 2001-08-02 | 2007-02-27 | Bidachem S.P.A. | Stable polymorph of flibanserin |
US20030060475A1 (en) * | 2001-08-10 | 2003-03-27 | Boehringer Ingelheim Pharma Kg | Method of using flibanserin for neuroprotection |
UA78974C2 (en) | 2001-10-20 | 2007-05-10 | Boehringer Ingelheim Pharma | Use of flibanserin for treating disorders of sexual desire |
US10675280B2 (en) | 2001-10-20 | 2020-06-09 | Sprout Pharmaceuticals, Inc. | Treating sexual desire disorders with flibanserin |
TW200508197A (en) * | 2003-03-31 | 2005-03-01 | Ucb Sa | Indolone-acetamide derivatives, processes for preparing them and their uses |
EP1719761A4 (fr) * | 2004-02-23 | 2007-10-10 | Dainippon Sumitomo Pharma Co | Nouveau compose heterocyclique |
US20050239798A1 (en) * | 2004-04-22 | 2005-10-27 | Boehringer Ingelheim Pharmaceuticals, Inc. | Method for the treatment of premenstrual and other female sexual disorders |
RU2445095C2 (ru) * | 2004-04-22 | 2012-03-20 | Бёрингер Ингельхайм Интернациональ Гмбх | Новые фармацевтические композиции для лечения сексуальных расстройств |
US20060025420A1 (en) * | 2004-07-30 | 2006-02-02 | Boehringer Ingelheimn International GmbH | Pharmaceutical compositions for the treatment of female sexual disorders |
CA2576812A1 (fr) * | 2004-09-03 | 2006-03-09 | Boehringer Ingelheim International Gmbh | Methode de traitement du trouble de l'hyperactivite avec deficit de l'attention |
EP1858516A1 (fr) * | 2005-03-04 | 2007-11-28 | Boehringer Ingelheim International GmbH | Compositions pharmaceutiques utiles dans le traitement et/ou la prevention de la depression |
US20060199805A1 (en) * | 2005-03-04 | 2006-09-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders |
WO2006096439A2 (fr) * | 2005-03-04 | 2006-09-14 | Boehringer Ingelheim International Gmbh | Compositions pharmaceutiques destinees au traitement et/ou a la prevention de la schizophrenie et de maladies associees |
EP1904182A2 (fr) * | 2005-05-06 | 2008-04-02 | Boehringer Ingelheim International GmbH | Methode de traitement de la toxicomanie avec flibanserine |
EP1888071A1 (fr) * | 2005-05-19 | 2008-02-20 | Boehringer Ingelheim International GmbH | Procede pour le traitement de dysfonctionnements sexuels d origine medicamenteuse |
EP1888070A1 (fr) * | 2005-05-19 | 2008-02-20 | Boehringer Ingelheim International GmbH | Procede pour le traitement de dysfonctionnements sexuels dus a des etats pathologiques |
US8227476B2 (en) | 2005-08-03 | 2012-07-24 | Sprout Pharmaceuticals, Inc. | Use of flibanserin in the treatment of obesity |
US7923449B2 (en) * | 2005-10-29 | 2011-04-12 | Boehringer Ingelheim International Gmbh | Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders |
US20070123540A1 (en) * | 2005-10-29 | 2007-05-31 | Angelo Ceci | Sexual desire enhancing medicaments comprising benzimidazolone derivatives |
US20070105869A1 (en) * | 2005-11-08 | 2007-05-10 | Stephane Pollentier | Use of flibanserin for the treatment of pre-menopausal sexual desire disorders |
AU2007247094B2 (en) * | 2006-05-09 | 2012-11-01 | Sprout Pharmaceuticals, Inc. | Use of flibanserin for the treatment of post-menopausal Sexual Desire Disorders |
CA2654798C (fr) | 2006-06-30 | 2015-01-13 | Boehringer Ingelheim International Gmbh | Flibanserine dans le traitement de l'incontinence urinaire et des maladies associees |
EP2043648A1 (fr) * | 2006-07-14 | 2009-04-08 | Boehringer Ingelheim International GmbH | Utilisation de flibansérine pour le traitement de troubles sexuels chez les femmes |
CL2007002214A1 (es) * | 2006-08-14 | 2008-03-07 | Boehringer Ingelheim Int | Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp |
AU2007286288A1 (en) * | 2006-08-14 | 2008-02-21 | Boehringer Ingelheim International Gmbh | Formulations of flibanserin and method for manufacturing the same |
WO2008022932A2 (fr) * | 2006-08-25 | 2008-02-28 | Boehringer Ingelheim International Gmbh | Système de libération contrôlée et procédé de préparation correspondant |
US8686008B2 (en) * | 2007-08-16 | 2014-04-01 | The University Of Mississippi | Highly selective sigma receptor ligands |
UY31335A1 (es) | 2007-09-12 | 2009-04-30 | Tratamiento de sintomas vasomotores |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA928296A (en) * | 1967-06-05 | 1973-06-12 | Umio Suminori | N-substituted and n, n-disubstituted aminocarbonylalkyl compounds and their production |
GB1270841A (en) * | 1969-03-28 | 1972-04-19 | Fujisawa Pharmaceutical Co | Benzothiazoline derivatives |
GR65270B (en) * | 1978-10-10 | 1980-07-31 | Fujisawa Pharmaceutical Co | Isatin derivatives and processes for the preparation thereof |
US4279909A (en) * | 1980-02-13 | 1981-07-21 | Fujisawa Pharmaceutical Co., Ltd. | Antiallergic method |
JPS6015276A (ja) * | 1983-07-04 | 1985-01-25 | Nissan Motor Co Ltd | 自動車組立工程における組付部品の仕様判別方法 |
JPS6063972A (ja) * | 1983-09-17 | 1985-04-12 | Sumitomo Electric Ind Ltd | クライオスタツト |
-
1986
- 1986-01-17 GB GB868601160A patent/GB8601160D0/en active Pending
- 1986-12-23 US US06/945,853 patent/US4797399A/en not_active Expired - Fee Related
- 1986-12-29 ZA ZA869748A patent/ZA869748B/xx unknown
- 1986-12-31 FI FI865369A patent/FI865369A/fi not_active Application Discontinuation
-
1987
- 1987-01-05 IL IL81172A patent/IL81172A0/xx unknown
- 1987-01-06 NO NO870053A patent/NO870053L/no unknown
- 1987-01-08 DK DK008687A patent/DK8687A/da unknown
- 1987-01-14 PT PT84103A patent/PT84103A/pt unknown
- 1987-01-15 EP EP87100448A patent/EP0232740A1/fr not_active Withdrawn
- 1987-01-16 JP JP62008379A patent/JPS62181253A/ja active Pending
- 1987-01-16 AU AU67626/87A patent/AU6762687A/en not_active Abandoned
- 1987-01-16 OA OA59044A patent/OA08462A/fr unknown
- 1987-01-17 KR KR870000328A patent/KR870007163A/ko not_active Application Discontinuation
- 1987-01-17 CN CN198787100707A patent/CN87100707A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
IL81172A0 (en) | 1987-08-31 |
JPS62181253A (ja) | 1987-08-08 |
EP0232740A1 (fr) | 1987-08-19 |
KR870007163A (ko) | 1987-08-17 |
DK8687A (da) | 1987-07-18 |
AU6762687A (en) | 1987-07-23 |
GB8601160D0 (en) | 1986-02-19 |
FI865369A (fi) | 1987-07-18 |
OA08462A (fr) | 1988-07-29 |
PT84103A (en) | 1987-02-01 |
US4797399A (en) | 1989-01-10 |
DK8687D0 (da) | 1987-01-08 |
CN87100707A (zh) | 1987-09-02 |
FI865369A0 (fi) | 1986-12-31 |
NO870053D0 (no) | 1987-01-06 |
ZA869748B (en) | 1987-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO870053L (no) | Fremgangsmaate for fremstilling av terapeutisk aktive nitrogenholdige, kondenserte, aromatiske forbindelser. | |
JP4869072B2 (ja) | Atp結合カセットトランスポーターのモジュレーターとして有用なチアゾールおよびオキサゾール | |
JP3334087B2 (ja) | 選択的ロイコトリエンb▲4▼拮抗剤活性を示す置換された二環式アリール化合物 | |
US7659283B2 (en) | Pyrrolo [3,2-C] pyridines useful as inhibitors of protein kinases | |
US3624104A (en) | Aralkanoyl derivatives of dibenzoxazepine-n-carboxylic acid hydrazides | |
JP2007502272A (ja) | 5‐HT2C受容体アゴニストとしての6‐(2,2,2‐トリフルオロエチルアミノ)‐7‐クロロ‐2,3,4,5‐テトラヒドロ‐1H‐ベンゾ[d]アゼピン | |
TW200914446A (en) | Certain substituted amides, method of making, and method of use thereof | |
CA2281518A1 (fr) | Derives 4,4-difluoro-2,3,4,5-tetrahydro-1h-1-benzazepines et compositions pharmaceutiques les contenant | |
WO2004111014A1 (fr) | Derives de pyrimidne utilises en tant que modulateurs de transporteurs de cassette de liaison a l'atp | |
RU2137760C1 (ru) | Производное бензазепина, фармацевтическая композиция, производное дифторбензазепина и производное (замещенного) аминобензоилдифторбензазепина | |
CA2185670A1 (fr) | Composes heterocycliques, leur preparation et leur utilisation | |
JPH0610193B2 (ja) | 新規1−置換オキシインド−ル−3−カルボキシアミド、その製法および抗炎症鎮痛組成物 | |
KR20160021817A (ko) | Fshr의 조절인자로서의 피라졸 화합물 및 이의 용도 | |
Sestili et al. | A new synthetic approach of N-(4-amino-2-methylquinolin-6-yl)-2-(4-ethylphenoxymethyl) benzamide (JTC-801) and its analogues and their pharmacological evaluation as nociceptin receptor (NOP) antagonists | |
EP0625983A1 (fr) | Derives heterotricycliques, leur procede de preparation, et compositions pharmaceutiques les contenant | |
US4725608A (en) | Semicarbazide derivatives, processes for preparation thereof and pharmaceutical composition comprising the same | |
HU203238B (en) | Process for producing antiinflammatory tricyclic oxindole derivatives | |
PT89119B (pt) | Processo para a preparacao de derivados de amidas aciclicas com actividade psicotropica | |
Collins et al. | 3-(1-Piperazinyl)-4, 5-dihydro-1H-benzo [g] indazoles: high affinity ligands for the human dopamine D4 receptor with improved selectivity over ion channels | |
ES2257168B1 (es) | Ligandos del receptor 5-ht7. | |
CN114634500B (zh) | 一种ptp1b抑制剂及其合成方法和用途 | |
ES2226726T3 (es) | Tetrahidroquinazolina-2,4-diona y usos terapeuticos de la misma. | |
JPS6239583A (ja) | ベンゾジオキソ−ル誘導体及びその製造法 | |
IL26032A (en) | 5-(n-acyl-3-indolyl)methyltetrazoles | |
CN114634503B (zh) | 含吲哚生物碱杂环取代-1,3-噻唑烷酮类衍生物及其制备方法和用途 |